TSC2 and neoplasm: Rapamycin has been shown to increase miR-29b, which promotes mTORC1-hyperactive growth in TSC2-deficient cells via downregulation of the TS retinoic acid receptor β, or reduction in miRNAs, such as miR-29b itself, to increase tumor suppressor pathways [94].